JOHN FREDERICK DE GROOT to Receptors, Vascular Endothelial Growth Factor
This is a "connection" page, showing publications JOHN FREDERICK DE GROOT has written about Receptors, Vascular Endothelial Growth Factor.
Connection Strength
1.698
-
VEGF Manipulation in Glioblastoma. Oncology (Williston Park). 2015 Oct; 29(10):720-7.
Score: 0.438
-
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol. 2013 Jun; 8(2):117-25.
Score: 0.363
-
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. Am Soc Clin Oncol Educ Book. 2013.
Score: 0.362
-
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 03; 132(1):181-188.
Score: 0.120
-
Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 12; 130(3):495-503.
Score: 0.117
-
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol. 2012 Nov; 14(11):1379-92.
Score: 0.089
-
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011 Jul 15; 17(14):4872-81.
Score: 0.081
-
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011 Jul 01; 29(19):2689-95.
Score: 0.081
-
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756.
Score: 0.031
-
VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 2008 Dec; 10(6):940-5.
Score: 0.017